Anzeige
Mehr »
Login
Samstag, 13.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Spezial: Montag letzte Chance vor großer Verkündung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Edison Investment Research

ZeitAktuelle NachrichtenRatingLeser
04.04.SIGA Technologies - Positive signals abound201SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth...
► Artikel lesen
03.04.Sareum Holdings - A decisive period ahead for SDC-180193Sareum Holdings' H124 results highlighted the company's swift progress for lead asset SDC-1801, since gaining regulatory approval in Australia to start human studies in mid-CY23. SDC-1801, a TYK2/JAK1...
► Artikel lesen
03.04.The Metals Company - Growing up237The Metals Company (TMC) is approaching a critical phase in its development. As key milestones are achieved, so the project will be de-risked and the valuation expand. Of particular note are the anticipated...
► Artikel lesen
03.04.Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T210Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with relapsed/refractory (r/r) amyloid light chain amyloidosis (ALA)....
► Artikel lesen
03.04.Cordel Group - Positive steps towards ambitious FY24 goals138Cordel's Q324 update shows progress towards the group's FY24 revenue expectation and other objectives, supporting our forecasts. Doubling the customer base by year-end is a key milestone, which encouragingly...
► Artikel lesen
03.04.Topps Tiles - Market tough through H124131Topps Tiles' (TPT's) H124 update shows that trading deteriorated further in Q224, following the weakness that began in Q124. Management attributes the decline to the soft external environment as noted...
► Artikel lesen
02.04.Solid State - Anticipating record adjusted PBT in FY24149Solid State's trading update affirms the sustained strength in demand throughout H224, resulting in record FY24 revenue and adjusted PBT ahead of prior consensus of £155m and £12.5m, respectively. This...
► Artikel lesen
02.04.Greggs - Showing us how it's done213The second full year of Greggs' five-year growth plan to double revenue by FY26 should be marked down as very successful, especially so given the challenging external environment. Unlike many consumer-facing...
► Artikel lesen
02.04.Information Services Corporation - A busy end to a record FY23141In FY23, Information Services Corporation (ISC) enjoyed year-on-year top-line and adjusted operating profit growth, augmented by consistent organic expansion of its Services division and incremental...
► Artikel lesen
02.04.OSE Immunotherapeutics - Pipeline momentum builds into FY24199OSE Immunotherapeutics' (OSE's) FY23 update summarised an active period for its clinical pipeline that was capped by the post-period $713m deal with AbbVie for preclinical asset OSE-230. The company...
► Artikel lesen
28.03.ABC arbitrage - FY23 results in line with market conditions207ABC arbitrage group (ABCA) reported net income of €16.5m in FY23, 43% lower than FY22, but in line with market conditions. Financial markets in 2023 were characterised by lower volatility than in the...
► Artikel lesen
28.03.Gym Group - The power of marginal gains195Gym Group has accompanied confirmation of FY23 profit resilience and continued buoyancy (like-for-like revenue up 12% in the first two months of 2024) with a clear commitment 'to accelerate, not reinvent...
► Artikel lesen
28.03.Mendus - Regulatory green light for CADENCE trial128The Human Research Ethics Committee (HREC) has provided the green light to commence enrolment for Mendus's AMLM22-CADENCE trial from April 2024. This Phase II trial in collaboration with the Australasian...
► Artikel lesen
28.03.Alpha Bank - Full steam ahead288Alpha Bank (Alpha) reported €611m in net profit, a 66% jump from FY22, as the bank benefited from an elevated interest rate environment with little impact from deposit migration and strong cost control....
► Artikel lesen
28.03.Dalata Hotel - A strong hand182Dalata's FY23 deployment of €156m in high-profile hotel opportunities in London, Amsterdam and Edinburgh as well as the newly announced proposed redevelopment at Manchester Airport show the scale and...
► Artikel lesen
28.03.S4 Capital - Extension of recovery horizon239S4 Capital had a difficult FY23, as flagged, with reduced client confidence and spend, particularly from those clients in the tech sector, and on larger transformation projects. Management is cautious...
► Artikel lesen
27.03.Datatec - FY24 revenue growth of 5.8%190Datatec expects to report revenue of $5.44bn for FY24, up 5.8% y-o-y, and noted that the quality of earnings improved in the year. During H224, Westcon International continued to deliver a strong financial...
► Artikel lesen
27.03.AG Barr - Fizzing away170AG Barr's (BAG's) FY23 results highlighted the strength of the brand portfolio as group volumes (+2.4%) outperformed the UK soft drinks category decline of 2.9%. Key brands IRN-BRU (33% of FY24 revenue)...
► Artikel lesen
27.03.Kolibri Global Energy - FY23 reserves show solid replacement rates184Kolibri (KEI) released its annual reserves statement, which showed good replacement rates despite a visible increase in average production in FY23. At end-2023, the company's total gross proved reserves...
► Artikel lesen
26.03.Recce Pharmaceuticals - R&D advance (A$11.18m) extends runway119Recce Pharmaceuticals recently received A$11.18m as an R&D advance credit through an arrangement with Endpoints Capital for the R&D tax credit rebates that Recce expects to receive for FY23/FY24 and...
► Artikel lesen
26.03.Immix Biopharma - Marching towards US clinical trials for NXC-201222Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer Center as the main clinical site for the company's...
► Artikel lesen
25.03.Ocean Wilsons Holdings - Strong FY23 results with strategic review in FY24155Ocean Wilsons Holdings' (OCN's) FY23 results highlight a robust performance from the Brazilian subsidiary Wilson Sons, as well as growth from the investment portfolio. Our forecasts are under review...
► Artikel lesen
25.03.Kinepolis - On the move165Kinepolis is 'ready to tango', according to management, after impressive FY23 results defied last year's Hollywood strikes (H2 adjusted EBITDA up 26% despite 2% fewer visitors in Q4). Its confidence...
► Artikel lesen
25.03.IRLAB Therapeutics - FDA thumbs up to mesdopetam's Phase III plan137IRLAB Therapeutics has confirmed the FDA's alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following receipt of the minutes from its end-of-Phase...
► Artikel lesen
25.03.Nano Dimension - Growth in a tough market212Nano Dimension made good progress growing revenue and gross margins in FY23. The company is now focused on reducing cash burn and moving to profitability, via its Reshaping Nano initiative, and is simultaneously...
► Artikel lesen